MetaCap

Allarity Therapeutics (ALLR) vs Neuphoria Therapeutics (NEUP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Allarity Therapeutics (ALLR) has outperformed Neuphoria Therapeutics (NEUP) over the past year, losing 25.9% versus a loss of 47.3%. Neuphoria Therapeutics is the larger company by market cap ($12.7 million vs $12.6 million), about 1.0 times the size. Neuphoria Therapeutics converts more of its revenue into profit, with a net margin of -1145.7% versus -3509.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALLR-25.94%NEUP-47.31%
+73%+9%-55%
Nov 21, 20251 yearNov 20, 2026
ALLR-100.00%NEUP-98.41%
+7%-49%-105%
Dec 20, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALLR versus NEUP key metrics
MetricALLRNEUP
Share price$0.785$2.35
Market cap$12.56M$12.72M
1-day change-9.25%+1.29%
YTD return-27.31%-39.43%
1-year return-25.94%-47.31%
EPS (TTM)$-0.79$-2.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$320.00K$1.17M
Revenue growth (YoY)—-92.50%
Net income (latest FY)$-11.23M$-13.45M
Operating margin-3939.06%-1401.09%
Net margin-3509.69%-1145.66%
52-week high$1.84$5.53
52-week low$0.769$2.26
Distance from 52-week high-57.34%-57.50%
Analyst consensusnonenone
Avg. price target upside+1301.27%—
Average volume131.74K26.53K
Shares outstanding16.00M5.41M
Employees71
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ALLR has outperformed NEUP by 21.4 percentage points over the past year.
  • Neuphoria Therapeutics is more profitable, keeping -1145.7 cents of every revenue dollar as net income versus -3509.7 cents for Allarity Therapeutics.

About Allarity Therapeutics

ALLR stock →

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Neuphoria Therapeutics

NEUP stock →

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

ALLR vs NEUP FAQ

Which is bigger, Allarity Therapeutics or Neuphoria Therapeutics?

Neuphoria Therapeutics (NEUP) is larger, with a market capitalization of $12.72M compared with $12.56M for Allarity Therapeutics (ALLR).

Which stock has performed better over the past year, ALLR or NEUP?

ALLR returned -25.94% over the past 12 months, compared with -47.31% for NEUP (price return, excluding dividends). Past performance does not predict future results.

Are Allarity Therapeutics and Neuphoria Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons